Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038

NEUROCRINE BIOSCIENCES INC

Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).
Prior settlements with Sandoz, Teva, and Lupin allow generic entry from March 1, 2038, subject to earlier triggers.
All ANDA-filing companies now settled, blocking generic competition until at least 2038, a significant IP win.
Settlements require FTC/DOJ review but are standard in Hatch-Waxman litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.